纤维蛋白胶瘤囊填充预防II型内漏的前瞻性随机对照试验短期结果
该前瞻性随机对照试验将64例腹主动脉瘤患者随机分为标准EVAR联合纤维蛋白胶瘤囊填充组(A组)与单纯标准EVAR组(B组),随访超过6个月。A组术后即刻造影II型内漏发生率9.6%显著低于B组33.3%(p=0.033),且6个月瘤囊面积变化显著减小(p=0.021);但6个月和1年随访时II型内漏发生率及1年AAA直径变化两组相似。作者结论认为纤维蛋白胶瘤囊填充可预防短期II型内漏并促进6个月后AAA缩小,但患者存在肠缺血风险,尤其在既往肠切除或合并肠系膜上动脉病变者。
要点
- A组术后即刻造影II型内漏发生率9.6%,显著低于B组33.3%(p=0.033)。
- A组6个月瘤囊面积变化显著减小(p=0.021),但6个月和1年II型内漏发生率及1年AAA直径变化两组相似。
- 作者指出纤维蛋白胶瘤囊填充操作快捷简便,但患者存在肠缺血风险,尤其既往肠切除或合并SMA病变者。
核心结论
- 纤维蛋白胶瘤囊填充可预防短期II型内漏并促进6个月后AAA缩小,操作快捷简便,但患者存在肠缺血风险,尤其既往肠切除或合并SMA病变者。
研究设计与样本
- 前瞻性随机对照试验,64例腹主动脉瘤患者随机分为A组(标准EVAR+纤维蛋白胶瘤囊填充)和B组(标准EVAR),所有患者随访超过6个月。
主要发现
- A组术后即刻造影II型内漏发生率9.6%,显著低于B组33.3%(p=0.033)。
- A组6个月瘤囊面积变化显著减小(p=0.021)。
- 6个月(p=0.055)和1年(p=0.057)随访时II型内漏发生率两组相似,1年AAA直径变化亦相似。
- 两组手术时间、辐射剂量、严重不良事件和再干预相似。
关键数值与推荐
- A组术后即刻造影II型内漏发生率9.6% vs B组33.3%(p=0.033)。
- 6个月瘤囊面积变化A组显著减小(p=0.021)。
- 6个月II型内漏发生率两组相似(p=0.055),1年两组相似(p=0.057)。
临床怎么用
- 作者认为纤维蛋白胶瘤囊填充是标准EVAR的有用补充,可能对破裂动脉瘤有潜在用途但无直接证据。
- 作者指出该操作快捷简便,但患者存在肠缺血风险,尤其既往肠切除或合并SMA病变者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type II endoleak (T2EL) worsens the long-term results of endovascular aneurysm repair (EVAR). How to prevent T2ELs remains controversial. This study aimed to evaluate the efficacy and safety of fibrin glue sac filling (FGSF) to prevent T2ELs after EVAR. METHODS: A prospective randomized controlled trial was conducted. Patients were randomly divided into group A (standard EVAR + FGSF) and group B (standard EVAR). The follow-up plans included outpatient or telephone consultation at 1 and 3 months and computed tomography (CT) angiography at 6 months, 1 year, and once a year after EVAR. RESULTS: A total of 64 abdominal aortic aneurysm (AAA) patients were randomized to the 2 groups. All patients were followed up for more than 6 months. The 2 groups showed similar baseline characteristics. The rate of T2ELs on immediate angiography in group A (9.6%) was significantly lower than that in group B (33.3%, p=0.033). Moreover, the sac area change was significantly reduced in group A at 6 months after EVAR (p=0.021). However, T2EL incidence was similar at the 6-month (p=0.055) and 1-year (p=0.057) follow-ups, and AAA diameter change was also similar at 1 year. There were similar operation times, radiation doses, severe adverse events (SAEs), and reinterventions between the 2 groups. CONCLUSION: Fibrin glue sac filling could prevent short-term type II endoleaks and promote AAA shrinkage after 6 months. The FGSF procedure is swift and straightforward; however, patients are at risk of bowel ischemia, especially after previous bowel resections or concomitant superior mesenteric artery (SMA) disease. CLINICAL IMPACT: Standard endovascular aneurysm repair (EVAR) couldn't prevent type II endoleak (T2EL). In this study, we found fibrin glue sac filling (FGSF) could prevent T2EL and promote AAA shrinkage in a short term. And the FGSF procedure is easy, it will be a useful supplement to standard EVAR for clinicians. And FGSF might have potential usefulness on ruptured aneurysms, although without direct evidence.Fibrin glue is often used to hemostasis and tissue adhesion in surgical patients and burn patients, we firstly carry out a randomized controlled study and prove that fibrin glue sac filling could prevent T2EL and promote sac remodeling.
引用
- Chen Y, Zhang L, Liu Z, et al. Fibrin Glue Sac Filling for Preventing Type II Endoleak, Short-Term Outcomes of a Prospective Randomized Controlled Trial. J Endovasc Ther. 2023. PMID: 36942722. doi:10.1177/15266028231159245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。